Erythropoietic protoporphyria (EPP) is a rare inherited metabolic disorder caused by a defect in porphyrin-heme biosynthesis. In this condition, excess protoporphyrin accumulates in red blood cells, plasma, and the liver, leading to painful and debilitating sensitivity to light. The condition encompasses several distinct subtypes with different underlying genetic bases and inheritance patterns. The most clinically recognized form — caused by reduced activity of the enzyme ferrochelatase — follows an autosomal recessive or autosomal dominant inheritance pattern depending on the specific variant context. A rarer subtype, X-linked protoporphyria (XLP), results from a gain-of-function change in a different gene and is inherited in an X-linked manner; available GeneReviews data referenced in this summary pertain specifically to this XLP subtype. EPP overall is rare, with XLP estimated to account for approximately 2 to 10 percent of individuals presenting with the erythropoietic protoporphyria phenotype, depending on geographic region. This summary reflects clinical data available as of 2026-05-10.

The hallmark feature of EPP and its XLP subtype is cutaneous photosensitivity, which typically begins in infancy or childhood and is usually lifelong. Affected individuals experience burning, tingling, pain, and itching of the skin within minutes of sun or bright light exposure. Erythema and swelling may follow the initial painful episode. Importantly, visible skin damage such as blistering and scarring is absent or sparse, which can make the diagnosis less immediately apparent to clinicians. The absence of obvious skin lesions often means symptoms may be dismissed or attributed to other causes. In the XLP subtype, males tend to have higher protoporphyrin levels and an increased risk of liver complications compared to those with the more common autosomal recessive form. Hepatic involvement, including cholestatic liver disease, may develop in a subset of individuals. Affected individuals frequently limit sun exposure substantially, which can result in vitamin D insufficiency. Anemia related to iron dynamics may occur. Not all individuals experience all features, and severity varies considerably.

EPP results from inherited defects in enzymes involved in the porphyrin-heme biosynthesis pathway, leading to protoporphyrin accumulation in erythrocytes, plasma, and liver tissue. Excess protoporphyrin is phototoxic — when activated by light, it generates reactive species that damage tissues, producing the characteristic photosensitivity symptoms. The specific genetic cause differs by subtype. In the XLP subtype, the condition is inherited in an X-linked manner, meaning the causative gene variant is located on the X chromosome; XLP is fully penetrant in males, while carrier females show variable clinical expression due to X-chromosome inactivation patterns. In the more common autosomal form, inheritance follows autosomal patterns. Specific gene names are not included in the current data packet and are not detailed here. Genetic counseling is strongly recommended for affected individuals and their families to assess heritable risk and appropriate testing strategies.

There are no universally established diagnostic guidelines or algorithms for EPP. The diagnosis should be considered in any individual presenting with painful cutaneous photosensitivity beginning in childhood, particularly when visible skin damage is absent or minimal. Key diagnostic findings include elevated erythrocyte protoporphyrin levels, with specific fractionation patterns (free versus zinc-chelated protoporphyrin) that differ between subtypes. Characteristic findings on blood and plasma porphyrin testing are central to diagnosis and subtype differentiation. Skin findings alone are not sufficient for diagnosis. Molecular genetic testing can identify the specific pathogenic variant and establish the subtype. Initial evaluation recommended at diagnosis includes assessment of erythrocyte protoporphyrin levels, complete blood count with indices to assess for anemia, iron studies including ferritin, and liver function tests given the risk of hepatic involvement. Imaging of the abdomen may be performed if gallstones are suspected. Consultation with a specialist in metabolic disease or hematology is recommended.

Afamelanotide, a synthetic analogue of alpha-melanocyte-stimulating hormone that increases skin melanin and reduces photosensitivity, received FDA approval in 2019 for the treatment of erythropoietic protoporphyria and is the only currently FDA-approved pharmacological therapy for this condition. It is administered as a subcutaneous implant and has been shown to increase the amount of time individuals can tolerate light exposure. Non-pharmacological protective measures remain important at all stages of management. These include consistent use of protective clothing — long sleeves, gloves, and wide-brimmed hats — as well as UV-filtering glass in vehicles and windows. Topical sunscreens are generally not effective for this condition. Oral beta-carotene has historically been used to improve light tolerance in some individuals, though its effects are variable. Individuals with hepatic involvement require careful monitoring and avoidance of agents that may worsen liver function, including alcohol and medications that can induce cholestasis (such as estrogens) in those with pre-existing liver disease. For individuals undergoing surgical procedures, protective filtering of operating room lighting may be needed to prevent phototoxic damage during procedures such as endoscopy or open surgery. Vitamin D levels should be monitored and supplemented as needed, given the predisposition to deficiency from sun avoidance.

The prognosis for most individuals with EPP is significantly shaped by the impact of photosensitivity on quality of life. Lifelong light avoidance affects daily activities, social participation, and occupational choices. For the majority of individuals, life expectancy is not substantially reduced; however, a subset develops progressive hepatic disease driven by protoporphyrin accumulation in the liver, which can progress to liver failure in severe cases. Annual surveillance — including liver function testing, erythrocyte protoporphyrin measurement, iron studies, and vitamin D monitoring — is recommended to detect and manage complications early. The availability of afamelanotide has meaningfully expanded the capacity for individuals to tolerate light exposure and improve functional quality of life. Ongoing monitoring for anemia and liver status is an integral part of long-term care.

The research landscape for EPP includes active clinical trials evaluating several investigational agents. Multiple phase 3 studies are ongoing for agents targeting the melanocortin pathway and for bitopertin, a glycine transport inhibitor, which holds orphan drug designation for EPP and is being studied in both EPP and XLP populations. Observational studies are collecting long-term natural history data to better characterize outcomes, quality of life, and the spectrum of disease severity across subtypes. Research in erythropoietic protoporphyria has expanded substantially in recent years, driven by the approval of afamelanotide and growing understanding of the disease's biochemical mechanisms. At least 6 active clinical studies are registered for this condition.